Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPN-305-102 Phase 0 follow-up in renal transplant patients
2012-005768-90Phase 2Completed
- Sponsor
- Opsona Therapeutics
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomaralimab in delayed graft function (DGF), sponsored by Opsona Therapeutics. Primary endpoint: Occurrence of allograft rejection or loss. Started Mar 2013; status: completed.
02
Drugs
tomaralimab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2012-005768-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005768-90.